A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102/SHR-9839(sc) with Adebrelimab with or without other Antitumor Therapy in Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. To explore the reasonable dosage of SHR-A2102/SHR-9839(sc) for Subjects with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Trial Details

NCT ID
NCT07059221
Phase
PHASE1 / PHASE2
Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Status
RECRUITING
Cancer Type
Squamous Cell Head and Neck Cancer
Interventions
  • SHR-A2102
  • Adebrelimab
  • Cetuximab
  • SHR-9839(sc)
  • Carboplatin / Cisplatin
Locations (sample)
  • Chongqing, Chongqing Municipality, China|29.56026,106.55771
  • Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

  • Have the ability to give informed consent, have signed informed and able to comply with the treatment plan to visit the tests and other procedural …
  • Subject with advanced or distant metastatic squamous cell carcinoma of the head and neck confirmed by histology or cytology.
  • At least one measurable lesion according to RECIST v1.1 criteria.
  • The ECOG score is 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Head and Neck Cancer Trials on Trialify →